Document is current
Any future updates will be listed below
-
Authors
Stadlbauer, Daniel https://orcid.org/0000-0001-6792-7650
Tan, Jessica https://orcid.org/0000-0001-8269-5560
Jiang, Kaijun
Hernandez, Matthew M. https://orcid.org/0000-0001-6217-7264
Fabre, Shelcie
Amanat, Fatima https://orcid.org/0000-0002-8029-8227
Teo, Catherine
Arunkumar, Guha Asthagiri https://orcid.org/0000-0003-3665-2708
McMahon, Meagan
Capuano, Christina
Twyman, Kathryn https://orcid.org/0000-0002-5222-5370
Jhang, Jeffrey
Nowak, Michael D.
Simon, Viviana
Sordillo, Emilia Mia https://orcid.org/0000-0001-7787-3051
van Bakel, Harm https://orcid.org/0000-0002-1376-6916
Krammer, Florian https://orcid.org/0000-0003-4121-776X
- License Information
-
More Information
Article History
Received: 12 July 2020
Accepted: 26 October 2020
First Online: 3 November 2020
Competing interests
: Mount Sinai has licensed serological assays to commercial entities and has filed for patent protection for serological assays. D.S., F.A., V.S. and F.K. are listed as inventors on the pending patent application (US provisional application no. 63/059,924). Mount Sinai has also founded a subsidiary, Kantaro Biosciences, to market a commercial version of the assay described in this manuscript. C.C., K.J., J.T., M.M.H., M.M., G.A.A., S.F., K.T., J.J., M.D.N., E.M.S., H.v.B. and C.T. declare no competing interests.
Free to read: This content has been made available to all.
